Ingevity (NGVT) Cash & Equivalents (2015 - 2026)

Ingevity (NGVT) has 12 years of Cash & Equivalents data on file, last reported at $95.4 million in Q1 2026.

• Quarterly Cash & Equivalents rose 33.43% year-over-year to $95.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.4 million (up 33.43% YoY) and the FY2025 annual result came in at $78.1 million, up 14.85% from the prior year.
• Cash & Equivalents grew to $95.4 million in Q1 2026 per NGVT's latest filing, from $78.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $222.6 million in Q1 2022 and bottomed at $68.0 million in Q2 2023.
• The 5-year median for Cash & Equivalents is $83.4 million (2025), against an average of $96.1 million.
• The widest annual swing landed in 2022, when Cash & Equivalents slumped 73.16%; it then jumped 60.36% in 2024.
• Tracing NGVT's Cash & Equivalents over 5 years: stood at $76.7 million in 2022, then increased by 25.03% to $95.9 million in 2023, then declined by 29.09% to $68.0 million in 2024, then increased by 14.85% to $78.1 million in 2025, then rose by 22.15% to $95.4 million in 2026.
• Per Business Quant, the three latest NGVT Cash & Equivalents figures stand at $95.4 million (Q1 2026), $78.1 million (Q4 2025), and $83.4 million (Q3 2025).

Peer Comparison